Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
SAGE Therapeutics (SAGE) Stock Price & Analysis
774 Followers
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.36 - $49.56
Previous Close$42.75
Volume798.40K
Average Volume (3M)500.12K
Market Cap
$2.55B
Enterprise Value$1.29B
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$12.13M
Price to Earnings (P/E)-4.8
Beta-0.20
Next Earnings
May 04, 2023EPS Estimate
-$2.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.98
Shares Outstanding59,717,608
10 Day Avg. Volume454,788
30 Day Avg. Volume500,121
Standard Deviation0.16
R-Squared0.16
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.97
Price to Sales (P/S)563.86
Price to Cash Flow (P/CF)2.90
P/FCF Ratio-8.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue168.15
Enterprise Value/Gross Profit188.06
Enterprise Value/Ebitda-2.37
Forecast
1Y Price Target
$52.64Price Target Upside23.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
SAGE Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $27.36 and its highest was $49.56 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is May 04, 2023 which is in 45 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Feb 16, 2023. The company reported -$2.47 earnings per share for the quarter, missing the consensus estimate of -$2.377 by -$0.093.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$2.49.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 59,717,610 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$2.47 in its last earnings report, missing expectations of -$2.377. Following the earnings report the stock price went down -0.111%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 17M.
---
SAGE Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$52.64 (23.13% Upside)
$52.64 (23.13% Upside)
Blogger Sentiment
Bearish
SAGE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 19.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $79.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.10%
12-Months-Change
Fundamentals
Return on Equity
-35.74%
Trailing 12-Months
Asset Growth
-25.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
---